By adopting the right investment strategy, the stock market offers numerous opportunities for building wealth, especially when the right equities are involved.
Now, with the current decade at its midpoint, certain companies are emerging as prime investment opportunities. Backed by strong fundamentals, these entities are poised to deliver high returns over the next five years, potentially elevating investors to millionaire status.
With that in mind, Finbold has identified two stocks that can potentially turn investors into millionaires within the next five years.
Picks for you
Broadcom (NASDAQ: AVGO)
Broadcom (NASDAQ: AVGO) is an ideal bet due to its inroads in artificial intelligence (AI) and the semiconductor sectors. Besides operating in a highly rewarding industry, several factors position Broadcom to stand out in the next five years.
First, Broadcom’s financial performance in 2024 highlights its strength. In its fiscal fourth quarter of 2024, revenue jumped 51% year-over-year to $14.05 billion, with AI revenue skyrocketing over 220%.
Part of this growth was driven by the technology giant’s strategic acquisition of VMware, which has expanded its reach into software solutions and solidified its position as a dual-threat player in semiconductors and infrastructure software.
Second, Broadcom’s role in the AI ecosystem is critical and offers more opportunities, considering its diversification. As a fabless semiconductor company, Broadcom boasts a strong client base, including Silicon Valley giants such as Meta (NASDAQ: META)
Additionally, Broadcom is strengthening its AI and connectivity leadership with new, unique products. For instance, the Bailly 51.2 Tbps Ethernet switch and VCSEL, EML, and CW laser technologies boost high-speed AI interconnects.
With such a product line, the firm is well-positioned for sustained growth as AI and cloud demand surge, potentially fueling long-term stock appreciation.
Meanwhile, Broadcom’s 2025 earnings per share (EPS) is projected to hit $6.35, with 2026 EPS expected to reach $7.60, reflecting steady profitability expansion.
On the revenue front, AVGO is forecasted to generate $61.28 billion in 2025, an 18.82% year-over-year increase, followed by $70.84 billion in 2026, marking a 15.61% growth. Currently, AVGO is trading at a price-to-earnings (P/E) ratio of 52.06, which suggests that the stock may be overvalued.
By press time, AVGO was trading at $199.45, ending the last trading session up 0.8%. However, year-to-date, the stock has struggled, plunging 14%.
Finally, as reported by Finbold, Wall Street remains highly bullish on AVGO’s prospects.
Eli Lilly (NYSE: LLY)
The pharmaceutical giant Eli Lilly (NYSE: LLY) remains a strong investment option primarily due to its essential in-demand drugs and a promising pipeline. Already, the stock is showing strength in 2025, making massive gains despite the recent market volatility.
By press time, LLY was trading at $920.63, up 1.71% from the close of the last trading session. In 2025, the stock is in the green, gaining over 18%.
The soaring demand for the firm’s weight loss and diabetes treatments, Zepbound and Mounjaro, makes LLY an ideal long-term growth stock. This is especially true considering the drugs’ impact is already significantly boosting Eli Lilly’s revenues.
For instance, in the last quarter of 2024, Eli Lilly reported revenue of $13.53 billion, a 45% year-over-year increase, and net income of $4.41 billion, with adjusted earnings per share of $5.32, beating Wall Street estimates of $4.95.
Mounjaro generated $3.53 billion in revenue for the quarter (up 60% YoY), while Zepbound, despite missing expectations, raked in $1.91 billion. Lilly is also set for further expansion, with plans to launch Mounjaro in new international markets and ramp up drug production by 1.6x in early 2025.
Additionally, its next-generation obesity drug, retatrutide, is expected to have late-stage data released earlier than anticipated, and the company projects 2025 sales between $58 billion and $61 billion.
Meanwhile, analysts estimate full-year 2025 revenue will reach $59.1 billion, reflecting a 31.2% year-over-year increase from $45.04 billion in 2024. Revenue is projected to grow further to $70.34 billion by 2026.
For Q1 2025, analysts expect $12.78 billion in revenue, a sharp 45.75% increase YoY, while Q2 revenue is forecasted at $14.25 billion, a 26.12% rise. EPS estimates are equally optimistic, with 2025 full-year EPS projected at $23.10, up from $12.99 in 2024. By 2026, EPS is expected to surge further to $29.05.
Regarding the investment strategy, if Broadcom compounds at 15% annually, investing $25,000 today could grow to over $100,000 by 2030.
Meanwhile, if Eli Lilly grows at 20% annually, investing $50,000 today could turn into $250,000. To reach the $1 million mark, investors may need to put in at least $100,000 upfront or consider higher-risk leverage strategies.
All in all, the highlighted stocks do not guarantee that investors will become millionaires by 2030 or any other timeframe, as returns depend on various factors, including market conditions, investment amount, and holding period.
Featured image via Shutterstock
